Relmada Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 125.75 million compared to USD 59.46 million a year ago. Basic loss per share from continuing operations was USD 7.16 compared to USD 3.81 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.69 USD | -2.12% |
|
-13.38% | -10.87% |
07-01 | Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index | CI |
07-01 | Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.87% | 114M | |
+19.93% | 126B | |
+23.36% | 118B | |
+23.26% | 27.87B | |
-18.20% | 20.95B | |
-15.13% | 16.92B | |
-13.60% | 16.18B | |
+10.09% | 14.84B | |
-46.10% | 14.79B | |
+52.36% | 14.08B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021